Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05766774

FEED-Cystic Fibrosis (FEED-CF)

The goal of this study is to determine the extent to which excess dietary sugars serve as a precipitating factor in glucose intolerance in adults with cystic fibrosis (CF), a population at especially high risk for a unique form of diabetes (CF-related diabetes, CFRD) and with standard-of-care dietary recommendations (high-calorie, high-fat) that conflict with recommendations for other forms of diabetes.

This trial will investigate if the typical high-sugar, high-fat CF diet plays a role in diabetes risk and visceral fat accumulation in people with CF. A total of 30 participants will get a low-added sugar, high-fat diet and the other 30 will get a standard CF diet with no sugar restrictions. Participants will be randomized to the diet group they are assigned. All foods will be provided for 8 weeks.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Emory University Hospital

Atlanta, Georgia, 30322, United States

Location status: Recruiting

Location contact

Swati Zaveri, PhD

CONTACT

[email protected]

440-778-8373

About this study

Approximately half of adults with cystic fibrosis (CF), a genetic disease, will develop diabetes. Dietary strategies shown to be successful in preventing or treating other forms of diabetes in people without CF contradict current nutritional recommendations for people with CF. The nutrition standard-of-care in CF is prescription of an unrestricted high-calorie, high-fat diet because of malnutrition. However, the standard CF diet translates to low-quality diets, with excess added sugars well-above general population recommendations. Also the investigators have shown that people with CF have more fat around their abdominal organs (called visceral fat) compared to healthy controls. The hypothesis is that the typical high-sugar, high-fat CF diet plays a role in diabetes risk and visceral fat accumulation in people with CF. In this study, the investigators will test if a low-added sugar diet improves risk markers for diabetes and decreases visceral fat over 8 weeks. The study will recruit 60 participants with CF. A total of 30 participants will get a low-added sugar, high-fat diet and the other 30 will get a standard CF diet with no sugar restrictions. Participants will be randomized to the diet group they are assigned. All foods will be provided for 8 weeks. There will be a total of 4 study visits at the Emory Hospital clinical research unit. These will include: 1) a screening visit with an oral glucose tolerance test with blood draws to determine if they already have diabetes, 2) a baseline visit for an insulin secretion test (called glucose-potentiated arginine (GPA) stimulation test) to assess risk for diabetes, as well as magnetic resonance imaging (MRI) testing to measure visceral fat, 3) a 4-week visit for another oral glucose tolerance test and in-person check-in, and 4) an 8-week visit for another GPA and MRI. Blood samples will be collected and banked. In addition to all meals provided for 8 weeks, participants will be compensated for their time and effort. Participants will be recruited from patients seen at the Emory CF Clinic. Informed consent will be performed prior to any study testing. The investigators hope this study will contribute to the development of new standardized nutrition guidelines for people living with CF.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed CF diagnosis
  • Ages 18 years and older
  • Baseline estimated daily total added sugar intake >16 tsp, as estimated from the Dietary Screener Questionnaire (DSQ).

Exclusion criteria

  • Nocturnal tube feeds
  • BMI <18.5 kg/m2
  • Life expectancy < 12 months
  • Confirmed diagnosis of CFRD
  • Screening OGTT showing fasting hyperglycemia (≥126 mg/dL)
  • Chronic steroid use
  • Current pregnancy or lactation
  • Inability/unwillingness to consume the majority of foods on the menu during the study period
  • MRI-incompatible metal that cannot be removed for testing
  • Uncontrolled exocrine pancreatic insufficiency/malabsorption
  • Clinically instability, defined as no changes in medical regimen (including medications and pulmonary exacerbations) for at least 21 days prior to study visit
  • Initiation of CFTR modulator within previous 8 weeks OR unstable changes in weight and lung function due to CFTR modulator use
  • Actively trying to gain or lose weight
  • Any food allergies or intolerances that cannot be accommodated
  • Any medical condition deemed by the a study physician or PI that may preclude completion of the study or interfere with primary end points.

Treatment and study plan

Low-added sugar, high-fat diet

Other

Consist of <5% kcal from added sugars as recommended by the American Heart Association, and the glycemic index will be 45 or lower (25% lower than typical CF diet). The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.

High-added sugar, high-fat CF diet

Other

Consist of ≥13% kcal from added sugars and the glycemic index will be >60. The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.

Other names: Typical CF diet

Primary outcomes

  1. Change in acute insulin response to arginine (AIRarg) from baseline

    Time frame: Baseline and 8 weeks post intervention

    Participants will undergo a Glucose-Potentiated Arginine Stimulation (GPA) Test after a 10-12 hour overnight fast to measure acute insulin (AIRarg) responses during a 230 and 340 mg/dl glucose clamp. This test will measure changes in beta cell secretory capacity.

  2. Change in acute C-peptide (ACRarg) from baseline

    Time frame: Baseline and 8 weeks post intervention

    Participants will undergo a Glucose-Potentiated Arginine Stimulation (GPA) Test after a 10-12 hour overnight fast to measure acute C-peptide (ACRarg) responses during a 230 and 340 mg/dl glucose clamp. This test will measure changes in beta cell secretory capacity.

  3. Change in visceral adipose tissue from baseline

    Time frame: Baseline and 8 weeks post intervention

    Dual energy X-ray absorptiometry (DEXA)-derived measurement of visceral adipose tissue (VAT) will be assessed with a GE Lunar iDXA machine. This will enable assessment of changes in body composition over the study.

  4. Change in fasted plasma Eh[CySS] from baseline

    Time frame: Baseline and 8 weeks post intervention

    Change in plasma Cysteine/Cystine Redox Potential (Eh[CySS]) will be measured.

Secondary outcomes

  1. Change in Gastrointestinal Symptom Rating Scale (GSRS) scale

    Time frame: Baseline and 8 weeks post intervention

    The GSRS is a 15 items combine into five symptom clusters: Reflux, Abdominal pain, Indigestion, Diarrhea and Constipation.

    Possible score range is 0-7, with 7 being the worst and 0 being the best (no symptoms).

  2. Change in hepatic and pancreatic fat volume

    Time frame: Baseline and 8 weeks post intervention

    Dual energy X-ray absorptiometry (DEXA)-derived measurement of visceral adipose tissue (VAT) for hepatic and pancreatic fat volume. Will be assessed with a GE Lunar iDXA machine.

  3. Change in fasted plasma Eh[GSSG]

    Time frame: Baseline and 8 weeks post intervention

    Change in plasma glutathione disulfide (GSSG) (Eh[CySS]) will be measured.

Study contacts

Contact information is provided by the study sponsor or research team.

Jessica A Alvarez, PhD, RD

CONTACT

[email protected]

404-727-1390

Swati Zaveri, PhD

CONTACT

[email protected]

440-778-8373

Sponsors and collaborators

Lead sponsor

Emory University

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Official study title

Feeding Study to Optimize Endocrine Dysfunction in Cystic Fibrosis

Acronym: FEED-CF

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
Mar 13, 2023
Registry last updated
Jun 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.